循环肿瘤 DNA (ctDNA) 状态知识对高危三阴性乳腺癌 (TNBC) 患者决策的影响尚不清楚，权衡获益和毒性。在这里，286 名有非转移性乳腺癌病史且接受过化疗的女性完成了一项调查，模拟化疗后残留 TNBC 的情况以及未知、阴性或阳性 ctDNA 状态，以确定接受辅助治疗决定的转变。然后向参与者呈现模拟可能的新辅助治疗后的场景并评估可接受性。具有重复测量的一般线性模型确定了风险降低和毒性的贡献。当假设的复发风险与 ctDNA 阴性相似时，与不接受治疗相比，接受卡培他滨辅助治疗的参与者明显减少。当 ctDNA 呈阳性且复发风险增加时，获益程度对可接受性的影响大于毒性特征。随着基因组技术的进步和 ctDNA 检测的商业化，了解其对患者决策的影响势在必行。© 2024。作者。

The impact of knowledge of circulating tumor DNA (ctDNA) status on patient decisions in high-risk triple-negative breast cancer (TNBC) weighing benefit and toxicity is unknown. Here, 286 women with a history of non-metastatic breast cancer who had received chemotherapy completed a survey mimicking scenarios of residual TNBC after chemotherapy and unknown, negative, or positive ctDNA status to determine the shift in the decision to receive adjuvant therapy. Participants were then presented scenarios mimicking possible post-neoadjuvant therapies and rated acceptability. A general linear model with repeated measures determined contributions of risk reduction and toxicity. When the hypothetical risk of recurrence mimicked ctDNA negativity, significantly less participants were accepting of adjuvant capecitabine versus no therapy. When presented with ctDNA positivity and increased recurrence risk, the degree of benefit impacted acceptability more than the toxicity profile. As genomic technology advances and ctDNA assays become commercially available, it is imperative to understand the impact on patient decision-making.© 2024. The Author(s).